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Clinical Observations
Effects of the Modified Linggui Zhugan Decoction (ࡴੇ㢧Ḗᴃ⫬∸)  
Combined with Short-term Very Low Calorie Diets on Glycemic Control 
in Newly Diagnosed Type 2 Diabetics 
CHEN Ding-sheng 䰜ϕ⫳ 1, KE Bin ᷃᭠ 1, HUANG Ying-juan咘乪࿳ 1, MENG Jun ᄳ৯ 1,  
ZHANG Jun-jie ᓴ֞ᵄ 1, CHEN Ze-xiong 䰜⋑䲘 1, MICHALSEN Andreas 2, and QIN Jian ⾺䡈 1
Objective: To evaluate the effects of the modified Linggui Zhugan Decoction (ࡴੇ㢧Ḗᴃ⫬∸) combined with 
short-term very low calorie diets (VLCDs) on glycemic control in newly diagnosed type 2 diabetes mellitus (T2DM) 
patients.  
Methods: A total of 20 subjects with newly diagnosed T2DM were treated with the modified Linggui Zhugan 
Decoction (one-month administration) combined with short-term VLCDs (5 days), and 3-months follow-up. A 
standard 75-g oral-glucose-tolerance test (OGTT) indexes fasting plasma glucose (FPG), post-prandial 0.5 h and 2 h 
plasma glucose (P0.5hPG, P2hPG), glycated hemoglobin A1C (GHbA1C), body weight, body mass index (BMI), 
insulin function, insulin resistance index, incidence of hypoglycemia, and the liver and renal functions were 
evaluated before and after treatment. Correlations of BMI with insulin function and insulin resistance were also 
assessed.  
Results: After the treatment, the patients’ plasma glucose decreased steadily, FPG decreased from 5.8±0.9 mmol/L 
at pre-treatment to 5.0±0.6 mmol/L at 3-months follow-up (P<0.05), and P2hPG decreased from 11.7±3.8 mmol/L 
at pre-treatment to 6.9±0.9 mmol/L at 3-months follow-up (P<0.01). The level of GHbA1C declined from 
(6.47±1.24)% at pre-treatment to (6.14±0.99)% at 3-months follow-up (P<0.01). Body weight and BMI also 
declined significantly. Insulin resistance index was improved obviously and no event of hypoglycemia occurred. 
Part of the patients companied with fatty liver had a transient increase in hepatic transaminase during the treatment, 
but it turned to normal after the treatment.  
Conclusions: The modified Linggui Zhugan Decoction combined with short-term VLCDs can be safely 
implemented for steady glycemic control in newly diagnosed T2DM patients. 
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Type 2 diabetes mellitus (T2DM) is a metabolic disorder 
with chronic course. The key pathogenic process 
involved in the onset of T2DM is insulin resistance with 
a ȕ-cell defect in insulin production. Insulin resistance in 
the main cause which and exists throughout the process, 
but only those with an inability to increase ȕ-cell 
production of insulin develop T2DM, followed by a 
vicious circle.1 A persistent hyperglycemia may 
aggravate ȕ-cell failure as well as insulin resistance.1, 2
Therefore, it is very important for the newly diagnosed 
T2DM patients to have an ideal glycemic control in a 
short time. 
The available researches have demonstrated that short- 
term intensive insulin therapy like continuous 
subcutaneous insulin infusion (CSII) or multiple daily 
insulin injection (MDI) may rapidly correct hyper- 
glycemia and lay a foundation for long-term good 
glycemic control in new-onset T2DM patients.3-7 CSII 
imitates the physiologic characteristic of insulin 
secretion in humans and delivers 24 h basal infusion 
rates continuously and a bolus dose to cover food eaten, 
provides intensive glycemia management and correct of 
the glucose toxicity in a short period.8, 9 Quantities of the 
data suggest that intensive insulin therapy may achieve 
the goals of correction of toxicities of glucose and lipid 
to ȕ-cell and prolong the benefit at the early stage in
diabetes patients.10
However,  the previous studies show that the risk of 
hypoglycemia in T2DM treated by insulin therapy was 
greater; and in intensive insulin therapy, the risk was 
even 3-fold higher than that of conventional diabetes 
management.11 More recently, reports have suggested 
that severe hypoglycemia may be reduced by CSII as 
much as 8-fold as compared with MDI treatment. But the 
cost of CSII treatment is about ̞170 a day,12 which 
most of the patients can’t afford. Moreover, the adverse 
effects of CSII, including allergic reactions, insulin 
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edema, hyperinsulinemia, weight gain, and reactions at 
injection area (inflammation, fever, itching and 
subcutaneous callosity, subcutaneous fat atrophy or 
fibrosis hyperplasia) make a discouraged clinical practice 
even in the developed countries.1 Considering the above 
situation, it is worthy to develop new economical 
alternative to control glycemia safely and effectively 
within a short time. 
Very low calorie diets (VLCDs) have drawn attention 
since 1990s due to its effect on weight loss to reduce the 
risk factors of cardiovascular disease in obese patients 
with T2DM.14-19 However, few of the randomized studies 
have specifically addressed the evidences of long-term 
effects of VLCDs on weight loss, glycemic control and 
reduction in risk factors of cardiovascular disease. A 
consensus statement from the International Diabetes 
Federation does not recommend the use of VLCDs in 
diabetes prevention due to lack of evidence for reduction 
of diabetic complications and mortality. 20,21 VLCDs are 
mainly used as a regimen for severe obese T2DM 
patients (body mass index (BMI), 35 kg/m2) in Western 
countries, and  BMI <25 kg/m2 as well as BMI 25–30 
kg/m2 are absolute and relative contraindications, 
respectively. 21, 22
The modified Linggui Zhugan Decoction (ࡴੇ㢧Ḗᴃ
⫬∸) combined with short-term VLCDs is a new kind of 
natural therapy incorporating of Chinese medicine with 
fasting therapy systematically.23 The treatment requires 
the participants not to have any solid food, but only drink 
millet soup. The modified Linggui Zhugan Decoction 
with the effects of warming and resolving the mucus, 
strengthening the spleen and removing the turbidity is 
simultaneously administered to restore normal function 
of the spleen in transportation and transformation. 24,25 In 
present study, we evaluated the effects of modified
Linggui Zhugan Decoction combined with short-term 
VLCDs on glycemic control in newly diagnosed T2DM 
patients. A report follows.  
METHODS 
Subjects 
Total 20 eligible patients (14 men and 6 women, 18 
inpatients and 2 outpatients.) participated in the 
treatment with the modified Linggui Zhugan Decoction 
combined with short-term VLCDs in the authors’ 
Chinese Medicine Department in the period starting from 
October 1st, 2009. The diagnosis of T2DM was in accord 
with the criteria issued by the WHO in 2006. Before the 
program began, all the subjects were fully informed 
about the course, effects and potential risks in the 
program, and then they gave the written informed 
consents. The protocols were approved by the Review 
Board and Ethical Committee for Clinic Research in the 
First Affiliate Hospital, Sun Yat-Sen University 
(Guangzhou, China).  
The mean age of all subjects was 49.4±10 (range 38-65) 
and the mean BMI was 29.3±5.1 kg/m2 (range 22.5-38.2). 
Treatment Protocol  
As previously described,25 the treatment fell into three 
phases: pre-treatment phase, VLCDs phase and restoring 
phase. The treatment was preceded by 3 relief days to 
decrease food intake gradually from the normal level to 
2/3 of the normal, and then to 1/3 of the normal; when 
the patients felt hungry, they may take some fruits or 
vegetables. Only fruits were allowed to be taken at the 
day they admitted in the hospital. The VLCDs phase (5 
days): at the first day, 10–20 g thenardite powder was 
used to clean the bowel. The modified Linggui Zhugan 
Decoction was administered twice a day, consisting of Fu 
Ling (Poria), Gui Zhi (Ramulus Cinnamomi), Bai Zhu 
(Atractylodes Macrocephaia), Gan Cao (Radix 
Glycyrrhizae), Dang Shen (Radix Codonopsitis) and Da 
Huang (Radix et Rhizome Rhei Palmati). And the 
patients were recommended to sip millet soup, which 
was boiled by 150 g millet added with 1 L water, and 
advised to drink 3 L of mineral water or moderate 
quantity of sports beverages to maintain electrolyte 
balance. But the solid food was forbidden during the 
VLCDS phase. In the restoring phase, the patients restore 
food intake by increasing the amount gradually, changing 
the fluid diet into solid food slowly, and from light diet 
to normal food, which lasted at least 3 days. After the 
above treatment, Chinese medicine decoctions were 
prescribed according to individual of the patients for a 
period of one month, and the patients were suggested to 
keep a healthy life-style. 
Evaluations 
1. Efficacy 
The OGTT indexes (FPG, P0.5hPG, P2hPG), GHbA1C, 
body weight, BMI, insulin function, and insulin 
resistance index were evaluated before and after 
treatment and during the follow-up period of three 
months. The correlations of BMI with insulin function 
and insulin resistance were also assessed. 
Plasma glucose was determined by the glucose oxidase 
technique, Insulin level was measured by radio- 
immunoassay, and GHbA1C level was tested by Bio-Rad 
HPLC. The function of ȕ cell and index of insulin 
resistance (IR) were calculated by Homeostasis Model 
Assessment (HOMA): HOMA-ȕ = 20 × fasting insulin 
level / (FPGˉ3.5), and HOMA-IR = FPG × fasting 
insulin level/22.5. 
2. Safety 
Hypoglycemic events, either the symptoms of strong 
hunger, palpitations, cold sweats, tremor, pale face or the 
monitored FPG 3.9 mmol/L, were recorded. The liver 
and renal functions were also observed. 
Statistical Analysis 
All the normal variables are expressed as mean ± 
standard deviation (mean ± SD). Data of pre- and post- 
treatment were compared using the paired-sample t test. 
Correlations of BMI to insulin function index and insulin 
resistance index were analyzed by Pearson correlation 
test. Differences were considered statistically significant 
at P<0.05 level. All the data were analyzed with the 
Statistical Package for Social Sciences (SPSS 17.0). 
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RESULTS 
Effects of Modified Linggui Zhugan Decoction 
Combined with Short-term VLCDs on Glycemic 
Control (Table 1)
All the patients included in the study showed an increase 
in post-prandial plasma glucose, but none of their FPG 
levels was 7 mmol/L before treatment. Significantly 
decreases of FPG, P0.5hPG and P2hPG were observed in 
post-treatment and 3-month follow-up compared with 
pre-treatment (P<0.05 or P<0.01), and these values in 
3-months follow-up didn’t change significantly 
compared with post-treatment. GHbA1c level decreased 
significantly in 3-months follow-up compared with 
pre-treatment (P<0. 01). 
Table 1. Changes of OGTT and GHbA1C parameters (20 patients, xfs) 
Measurement Time FPG (mmol/L) P0.5hPG (mmol/L) P2hPG (mmol/L) GHbA1c (%) 
Pre-treatment 5.8±0.9 10.5±2.3 11.7±3.8 6.47±1.24 
Post-treatment 4.8±0.8*    8.6±1.6**  8.1±2.3** ̢
3-months follow-up 5.0±0.6*    8.6±1.2**  6.9±0.9**   6.14±0.99**
Notes: OGTT, oral glucose tolerance test. FPG, fasting plasma glucose. P0.5hPG, post-prandial 0.5 h plasma glucose. P2hPG, post- 
prandial 2 h plasma glucose. GHbA1C, glycated hemoglobin A1C. Data is expressed as mean ± SD. *P<0.05, compared with pre-treatment; 
**P<0.01, compared with pre-treatment.
Effects of the Modified Linggui Zhugan Decoction 
Combined with Short-term VLCDs on BMI and 
Insulin Function (Table 2) 
The parameters of body weight, BMI, and HOMA-IR 
decreased significantly in post-treatment and 3-month 
follow-up compared with pre-treatment (P<0. 05 or P<  
0. 01), and these values in 3-month follow-up didn’t 
change significantly compared with post-treatment. 
There was no obvious difference in HOMA-ȕ throughout 
the study. The changes of body weight and BMI were not 
associated with HOMA-IR. 
Table 2. Changes of BMI and insulin function parameters (20 patients, xfs) 
Body weight (kg) BMI (kg/m2) HOMA-ȕ HOMA-IR 
Pre-treatment 84.8±23.3 29.3±5.1 159.3±88.3   4.1±1.7 
Post-treatment 80.7±21.4*  27.9±4.6 275.2±325.9   2.3±1.1
3-months follow-up 80.4±20.9*  27.8±4.5 149.5±84.6   2.2±0.9
Notes: BMI, body mass index. HOMA, Homeostasis Model Assessment. IR, insulin resistance. Data is expressed as mean ± SD. *P<0.05, 
compared with pre-treatment; P<0.01, compared with pre-treatment. 
Adverse Reactions 
No hypoglycemic events were found in all the 20 
subjects during the program, including 4 patients 
susceptible to hypoglycemia. 
Six patients showed higher hepatic transaminase (alanine 
aminotransferase (ALT) 40 IU/L and/or aspartate amin-
otransferase (AST) 37 IU/L) before treatment, and the 
indexes increased further during the treatment. And in 
one of the other 14 patients with normal level of ALT and 
AST, BMI was extremely high (38.2 kg/m2) after 
treatment. However, the elevated ALT and AST in all the 
7 patients returned to normal when rechecked one month 
later. All 20 subjects did not show any renal impairment.  
DISCUSSION 
The modified Linggui Zhugan Decoction in combination 
with short-term VLCDs in a new therapy of Chinese 
medicine integrated with German fasting therapy,23
which develops natural characteristics in VLCDs. Millet 
with rich nutrition value, containing 9.2%–14.7% protein, 
3.0%–4.6% fat, vitamin B1 and inorganic salt, can 
strengthen the Spleen and harmonize the Stomach. The 
modified Linggui Zhugan Decoction and millet soup can 
effectively promote the Spleen function in transportation 
and transformation.  
The present therapy showed a rapid control of glycemia 
without rebound in 3-month follow-up in the newly 
diagnosed T2DM patients, and GHbA1C decreased to 
normal level, suggesting that it may have the effects 
similar to intensive insulin therapy. That no events of 
hypoglycemia were found in all the 20 subjects indicates 
that the safety of the treatment is superior to intensive 
insulin therapy. And the treatment lasted only 5 days, 
with a period much shorter than that of VLCDs usually 
for over one month,16,18,22,26 which may greatly promote 
the patients’ acceptance.  
According to the results of HOMA, there was no change 
in £-cell function throughout the study, but the index of 
IR in 3-month follow-up decreased obviously as 
compared with that of pre-treatment, suggesting that the 
potential mechanism for rapid glycemic control of our 
intervention may be associated with improvement of 
insulin resistance. 
Generally, VLCDs achieves the benefits in prevention of 
T2DM by weight loss. 21 Whereas, it was found from the 
presest study that the decreases of body weight and BMI 
were not correlated to the improvement of insulin 
resistance. The reason may refer to the insufficient 
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subjects, and the mechanism of our intervention is not 
the mere function of weight loss. 
In the 3-month follow-up, the plasma glucose, BMI and 
IR kept stable as compared with those of post-treatment, 
indicating that the effects of the Modified Linggui
Zhugan Decoction combined with short-term VLCDs 
could be maintained at least for 3 months. 
Seven patients had higher hepatic transaminase and BMI 
>25 kg/m2 with a history of fatty liver before the 
program, and they underwent a further increase of 
transaminase during the treatment. But, the indexes
returned to normal when rechecked one month later. 
Transient rise in transaminase may be possibly due to the 
rapid mobilization of intracellular triglycerides and the 
fatty acid release causing the portal inflammation,21 or 
due to hepatic overload of ketogenesis.27 However, the 
long-term effect of the treatment is beneficial to 
improvement of the liver function. 
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